Lymph node ratio as best prognostic factor in triple‐negative breast cancer patients with residual disease after neoadjuvant chemotherapy

Author:

De la Cruz‐Ku Gabriel A.12ORCID,Chambergo‐Michilot Diego1ORCID,Valcarcel Bryan3ORCID,Rebaza Pamela2,Möller Mecker4,Araujo Jhajaira M.5ORCID,Enriquez Daniel6ORCID,Morante Zaida6,Razuri Cesar7,Luque Renato1,Saavedra Antonella1,Eyzaguirre Eduardo1,Lujan Maria1,Noel Naysha1,Pinto Joseph2ORCID,Cotrina Jose4,Gomez Henry28ORCID

Affiliation:

1. Universidad Científica del Sur Lima Perú

2. Unidad de Investigación Básica y TranslacionalOncosalud‐AUNA Lima Peru

3. Milken Institute School of Public Health The George Washington University Washington DC USA

4. Division of Surgical Oncology University of Miami Miller School of Medicine Jackson Memorial Hospital/Sylvester Comprehensive Cancer Center Miami FL USA

5. Escuela de Medicina Humana Universidad Privada San Juan Bautista Lima Perú

6. Department of Hematology and Medical Oncology Instituto Nacional de Enfermedades Neoplasicas Lima Peru

7. Division of General Surgery Hospital Nacional Dos de Mayo Lima Peru

8. Department of Breast Surgical Oncology Instituto Nacional de Enfermedades Neoplasicas Lima Peru

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Reference34 articles.

1. The Global Cancer Observatory.Peru. Source: Globocal 2018. In: Globocan [Internet]. WHO: Globocan 2018. Available from:https://gco.iarc.fr/today/data/factsheets/populations/604‐peru‐fact‐sheets.pdf

2. The Global Cancer Observatory.United States of America. Source: Globocal 2018. In: Globocan [Internet]. WHO: Globocan 2018. Available from:https://gco.iarc.fr/today/data/factsheets/populations/840‐united‐states‐of‐america‐fact‐sheets.pdf

3. Survival Study of Triple-Negative and Non–Triple-Negative Breast Cancer in a Brazilian Cohort

4. Eight year survival analysis of patients with triple negative breast cancer in India;Chandra D;Asian Pac J Cancer Prev,2016

5. Survival of triple negative versus triple positive breast cancers: comparison and contrast;Negi P;Asian Pac J Cancer Prev,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3